Neurogene (NASDAQ:NGNE) Price Target Lowered to $51.00 at HC Wainwright

Neurogene (NASDAQ:NGNEFree Report) had its target price lowered by HC Wainwright from $55.00 to $51.00 in a research note issued to investors on Monday morning, Benzinga reports. The brokerage currently has a buy rating on the stock. HC Wainwright also issued estimates for Neurogene’s Q2 2024 earnings at ($1.02) EPS, Q3 2024 earnings at ($1.04) EPS, Q4 2024 earnings at ($1.07) EPS, FY2024 earnings at ($4.14) EPS, Q1 2025 earnings at ($1.10) EPS, Q2 2025 earnings at ($1.12) EPS, Q3 2025 earnings at ($1.15) EPS, Q4 2025 earnings at ($1.17) EPS and FY2025 earnings at ($4.54) EPS.

Other equities research analysts have also recently issued research reports about the stock. Leerink Partnrs reiterated an outperform rating on shares of Neurogene in a report on Monday, April 29th. William Blair initiated coverage on Neurogene in a report on Thursday, March 21st. They issued an outperform rating and a $61.00 target price for the company. Finally, SVB Leerink assumed coverage on Neurogene in a report on Monday, April 29th. They set an outperform rating and a $46.00 price target on the stock. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of Buy and a consensus price target of $47.25.

View Our Latest Report on Neurogene

Neurogene Trading Up 6.5 %

Shares of Neurogene stock opened at $33.59 on Monday. Neurogene has a 1 year low of $12.20 and a 1 year high of $53.00. The stock has a 50-day moving average price of $38.22.

Institutional Investors Weigh In On Neurogene

Hedge funds have recently added to or reduced their stakes in the stock. SG Americas Securities LLC purchased a new position in shares of Neurogene in the 1st quarter worth $120,000. Privium Fund Management UK Ltd purchased a new position in Neurogene in the first quarter worth about $274,000. BML Capital Management LLC purchased a new position in Neurogene in the fourth quarter worth about $478,000. Avidity Partners Management LP bought a new stake in shares of Neurogene during the 4th quarter valued at about $9,036,000. Finally, Great Point Partners LLC purchased a new stake in shares of Neurogene during the 4th quarter valued at about $19,268,000. 52.37% of the stock is currently owned by hedge funds and other institutional investors.

About Neurogene

(Get Free Report)

Neurogene Inc, a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.

See Also

Analyst Recommendations for Neurogene (NASDAQ:NGNE)

Receive News & Ratings for Neurogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurogene and related companies with MarketBeat.com's FREE daily email newsletter.